The Role of GM-CSF in the Treatment of Acute Myeloid Leukemia

References

• Büchner Th., Hiddemann W., Koenigsmann M., Zühlsdorf M., Wörmann B., Boeckmann A., Aguion-Freire E., In-Nig G., Maschmeyer G., Ludwig W.D., Sauerland M.C., Heinecke A., Schulz G. Recombinant granulo-cyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 1991; 78: 1190–1197
   PubMed Web of Science ®Google Scholar
• Ohno R., Tomonaga M., Kobayashi T. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N. Engl. J. Med. 1990; 323: 871–877
   PubMed Web of Science ®Google Scholar
• Griffin J. D., Young D., Henmann F., Wiper D., Wagner K., Sabbath K. D. Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic Leukemia. Blood 1986; 67: 1448
   PubMed Web of Science ®Google Scholar
• Miyauchi J., Kelleher C. A., Yang Y., Wong G. C., Clark S. C., Minden M. D., Minken S., McCulloch E. A. The effect of three recombinant growth factors, IL-3, GM-CSF, and G-CSF, on the blast cells of acute myeloblastic leukemia maintained in short-term suspension culture. Blood 1987; 70: 657
   PubMed Web of Science ®Google Scholar
• Kelleher C., Miyauchi J., Wong G., Clark S., Minden M. D., McCulloch E. A. Synergism between recombinant growth factors GM-CSF and G-CSF, acting on the blast cells of acute myeloblastic leukemia. Blood 1987; 69: 1489
   Google Scholar
• Vellenga E., Young D. C., Wagner K., Wiper D., Os-Tapovicz D., Griffing J. D. The effect of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood 1987; 69: 1771
   PubMed Web of Science ®Google Scholar
• Cannistra S. A., Groshek P., Griffin J. D. Gran-ulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia 1989; 3: 328–334
   PubMed Web of Science ®Google Scholar
• Bettelheim P., Valent P., Andreeff M., Tafuri A., Haimi J., Gorischek C., Muhm M., Sillaber C. H., Haas O., Vieder L., Maurer D., Schulz G., Speiser W., Geissler K., Kier P., Hinterberger W., Lechner K. Recombinant human granulocyte-macrophage colony-stimulating factor in the de novo acute myeloid leukemia. Blood 1991; 77: 700–711
   PubMed Web of Science ®Google Scholar
• Reuter C. H., Auf der Landwehr U., Schleyer E., Zühlsdorf M., Ameling C. H., Rolf C., Wörmann B., Büchner Th., Hiddemann W. Modulation of intracellular metabolism of cytosine arabino side in acute myeloid leukemia by granulocyte-macrophage colony stimulating factor. Leukemia 1993, in press
   Google Scholar
• Koistinen P., Wang C., Curtis J. E., McCulloch E. A. Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast cells from ara-C toxicity. Leukemia 1991; 5: 789–795
   PubMed Web of Science ®Google Scholar
• Estey E. H., Thall P. F., Kantarjian H., O'Brien S., Koller C. A., Beran M., Gutterman J., Deisseroth A., Keating M. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSFI before and during continuous-infusion high-dose ara-C + daunorubicin: Comparison to patients treated without GM-CSF. Blood 1992; 79: 2246–2255
   PubMed Web of Science ®Google Scholar
• Lotem J., Sachs L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor β 1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood 1992; 80: 1750–1757
   PubMed Web of Science ®Google Scholar
• Bhalla K., Tang C., Ibrado A. M., Grant S., Tourkina E., Holladay C., Hughes M., Mahoney M. E., Huang Y. Granulocyte-macrophage colony-stimulating fac-tor/interleukin-3 fusion protein (PIXY 321) enhances high-dose ara-C-induced programmed cell death or apoptosis in human myeloid leukemia cells. Blood 1992; 80: 2883–2890
   PubMed Web of Science ®Google Scholar
• Biichner Th., Urbanitz D., Hiddemann W., Ludwig W.D., Fischer J., Aul H. C., Vaupel H. A., Kuse R., Zeile G., Nowrousian M. R., König H. J., Walter M., Wendt F. C., Sodomann H., Hossfeld D. K., von Paleske A., Löffler H., Gassmann W., Hellriegel K.P., Fülle H. H., Lun-Scken C. H., Emmerich B., Pralle H., Pees H. W., Pfreundschuh M., Bartels H., Koeppen K.M., Schwerdt-Feger R., Donhuijsen-Ant R., Mainzer K., Bonfert B., Köppler H., Zurborn K.H., Ranft K., Thiel E., Heinecke A. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): Two multi center studies of the German AML Cooperative Group. J. Clin. Oncol. 1985; 3: 1583–1589
   PubMed Web of Science ®Google Scholar
• Hiddemann W., Kreutzmann H., Straif K., Ludwig W.D., Mertelsmann R., Donhuijsen-Ant R., Lengfelder E., Arlin Z., Büchner Th. High-dose cytosine-arabinoside and mitoxantrone: A highly effective regimen in refractory acute myeloid leukemia. Blood 1987; 69: 744
   PubMed Web of Science ®Google Scholar
• Biichner T., Hiddemann W., Löffler G., Gassniann W., Maschmeyer G., Heit W., Hossfeld D., Weh H., Ludwig W.D., Thiel M., Nowrousian M., Aul C., Lengfelder E., Lathan B., Mainzer K., Urbanitz D., Emmerich B., Mid-Delhoff G., Donhuijsen-Ant H. R., Hellriegel H.P., Heinecke A. Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: Data from the AML Cooperative Group. Semin. Hematol. 1991; 28: 76–79
   PubMed Web of Science ®Google Scholar
• Büchner T., Hiddemann W., Koenigsmann M., Zühlsdorf M., Wörmann B., Boeckmann A., Aguion-Freire E., In-Nig G., Maschmeyer G., Ludwig W.D., Sauerland M.C., Heinecke A., Schulz G. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 1991; 78: 1190–1197
   PubMed Web of Science ®Google Scholar